Related Experiment Video
Updated: Aug 19, 2025
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
13.2K
Prescribed anti-glaucoma medication consumption and road traffic crash
Li Lu1,2,3, Benjamin Contrand2,3, Cedric Schweitzer4,5
1Health Management and Policy Institute, School of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, China.
Pharmacoepidemiology and Drug Safety
|November 29, 2022
Summary
Drivers using anti-glaucoma medications are not at increased risk of traffic crashes. This study found that prescribed anti-glaucoma medicine use was less frequent in crash-involved drivers, suggesting safe driving practices are effective.
Area of Science:
- Ophthalmology
- Traffic Safety
- Pharmacology
Background:
- Glaucoma is a leading cause of visual impairment globally.
- Visual deficits and glaucoma medication side effects raise traffic safety concerns.
- The study investigates the link between anti-glaucoma drug use and crash risk.
Purpose of the Study:
- To determine if anti-glaucoma medication use is associated with a higher likelihood of traffic crashes.
- To assess the relationship between anti-glaucoma drug consumption and crash responsibility.
Main Methods:
- Utilized French national databases (CESIR project) from 2005-2015.
- Included over 200,000 drivers involved in injurious crashes and a matched control group.
- Compared anti-glaucoma medication exposure between crash-involved and control drivers, and between responsible and non-responsible drivers.
Main Results:
- Anti-glaucoma medication prescriptions increased with age.
- Use of one or more anti-glaucoma medications was less common in crash-involved drivers compared to controls.
- No association was found between anti-glaucoma medication use and crash responsibility.
Conclusions:
- Findings are reassuring for individuals with glaucoma who drive.
- Existing guidelines for safe driving with anti-glaucoma medications appear effective.
- Driving behavior adaptations effectively mitigate traffic crash risks for glaucoma patients.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
520
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
520
01:25Glaucoma: Overview
685
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
685
01:28Angle Closure Glaucoma: Treatment
613
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
613
01:19Pharmacovigilance
951
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
951
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
591
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
591
01:24Cholinergic Antagonists: Pharmacokinetics
540
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
540